Clinical trials show that participants regained approximately two-thirds of their lost weight within one year of stopping the medication, reflecting obesity's chronic nature and biological adaptations that promote weight regain
Back Lasker Foundation (2024) 'GLP-1-based therapy for obesity'
(Refer to Table 1 for details of clinical trials evaluating GLP-1 and insulin)
A dual GLP-1/GIP receptor agonist An ideal antidiabetic medication should present proven efficacy in lowering elevated glucose levels, promote weight loss, have low risk of hypoglycemia and offer cardiovascular benefits [18]
Statistical analysis A 1:1 PSM was performed using the aforementioned covariates, utilizing a greedy nearest neighbor algorithm with a 0.1 pooled standard deviation caliper to minimize confounding between the groups
Golden milk, curries, and turmeric-spiced meals are all effective delivery methods